Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

In the trials, tirzepatide (Mounjaro, Eli Lilly) was associated with a mean weight loss of about 26% in both trials, with a safety profile similar to that previously reported in other SURMOUNT ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Eli Lilly's tirzepatide helped people lose up to 50 pounds, the sort of weight loss results only consistently seen with bariatric surgery. ... The trial was run in the U.S., Argentina, Brazil, ...

Lilly’s Zepbound ® (tirzepatide) superior to Wegovy ® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs 13.7%. News release. Eli Lilly and Company.